Comparing the current results to its competitors, Crispr Therapeutics Ag reported Revenue increase in the 2 quarter 2026 by 1041.37 % year on year. The sales growth was above Crispr Therapeutics Ag's competitors' average revenue growth of 77.11 %, achieved in the same quarter.
Crispr Therapeutics Ag's Comment on Competition and Industry Peers
CRISPR Therapeutics AG operates in the pharmaceutical and biotechnology sectors, focusing on genomic medicines such as gene editing, gene therapy, nucleic acid therapy, and cell therapy. The company faces competition from various entities, including large pharmaceutical and specialty pharmaceutical companies, biotechnology firms, academic institutions, governmental agencies, and research institutions. Key competitors in gene editing using CRISPR/Cas technology include Editas Medicine, Intellia Therapeutics, Metagenomi, and Scribe Therapeutics. Additional competitors in gene editing and delivery vectors comprise 4D Molecular Therapeutics, AskBio, Passage Bio, Sarepta Therapeutics, UniQure, and Voyager Therapeutics. In the nucleic acid therapy segment, competitors include Alnylam, Arrowhead Therapeutics, Avidity Biosciences, Bayer, Biogen, Dyne Therapeutics, Eli Lilly, Ionis Pharmaceuticals, Novartis, Novo Nordisk, Sarepta Therapeutics, Stoke Therapeutics, and Wave Life Sciences.
Due to outstanding performance in Overall company, revenue grew by 1041.37 % Crispr Therapeutics Ag improved its market share, to approximately 0.37 %.
January 16, 2024
The field of gene editing and therapeutic techniques has recently witnessed a monumental stride as the FDA (U.S. Food and Drug Administration) sanctions a pioneer gene-editing treatment for Transfusion-Dependent Beta Thalassemia (TDT). The approach, CASGEVY (exagamglogene autotemcel), manufactured by CRISPR Therapeutics, manifests an innovative potential for gene-editing technology in the pharmaceutical scene.Beta Thalassemia is a perilously severe genetic blood disorder characterized by chronic anemia, fatigue, and an excess of iron in the blood, resulting from the inadequate production of hemoglobin. For TDT patients, frequent blood transfusions become a distressing norm of life. CASGEVY advances a unique ...
Editas Medicine Inc.'s business model revolves around developing and commercializing transformative genome editing technologies to treat serious diseases.
Lexeo Therapeutics Inc is a biotechnology company focused on developing advanced gene therapies for the treatment of genetic disorders. Their business model revolves around leveraging cutting-edge technology and scientific expertise to develop innovative gene therapies that address significant unmet medical needs. They aim to bring these therapies to market through strategic partnerships and collaborations with pharmaceutical companies and academic institutions.
MeiraGTx Holdings Plc is a biotechnology company focused on developing gene therapies for inherited and acquired diseases. They leverage their proprietary technology to develop and commercialize innovative treatments that address unmet medical needs.
Maxcyte Inc's business model revolves around providing cell engineering and flow electroporation technology to facilitate drug discovery, development, and manufacturing processes.
Sources:
Crispr Therapeutics Ag’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Crispr Therapeutics Ag versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
